FDA issues first approval for a diabetes medicine that slows progression of CKD
For individuals living with diabetes—the leading cause of kidney failure—the approval by the U.S. Food and Drug Administration of the diabetes medicine canagliflozin (brand name INVOKANA®) to treat diabetic kidney disease and reduce the risk of hospitalization for heart failure patients with type 2 diabetes and diabetic kidney disease is cause for optimism. It is the first new treatment in decades for diabetic kidney disease.
About 1 in 3 adults with diabetes may also have kidney disease, and diabetes causes about 38% of all new cases of kidney failure. The ability to slow down the progression of kidney disease in patients with diabetes could, over time, begin to decrease the number of people who reach kidney failure—a significant development in the fight against a disease that affects 37 million Americans.
INVOKANA from the Janssen Pharmaceutical Companies of Johnson & Johnson is a type of drug known as an SGLT2 inhibitor. The FDA approval follows the results of the phase 3 CREDENCE clinical trial which found that, compared with people taking a placebo, patients taking INVOKANA were 30% less likely to progress to kidney failure or to die from either kidney failure or cardiovascular disease.
"We know that the real battle to turn the tide on kidney disease is in early detection and slowing its progression so that patients stay healthier and fewer patients reach kidney failure,” said LaVarne A. Burton, AKF president and CEO, in the press release announcing the FDA’s approval. “We are so grateful that advances in kidney disease research are producing treatment options that help to slow the progression of diabetic kidney disease and reduce the risk of hospitalization for heart failure."